Antimullerian hormone as a predictor of good-quality supernumerary blastocyst cryopreservation among women with levels <1 ng mL versus 1 4 ng mL
Antimullerian hormone (AMH) levels <1 ng/mL are associated with a statistically significantly lower likelihood of supernumerary good-quality blastocyst cryopreservation as compared with AMH levels between 1 and 4 ng/mL. Authors:
Shahryar K. Kavoussi, M.D., M.P.H., Kate C. Odenwald, M.S.N., R.N., Lynn M. Boehnlein, B.S., Roxanne B. Summers-Colquitt, M.S., Thomas B. Pool, Ph.D., Jason E. Swain, Ph.D., Jeffrey M. Jones, Ph.D., Mary J. Lindstrom, Ph.D., Dan I. Lebovic, M.D.
Volume 104, Issue 3, Pages 633-636
To determine whether antimüllerian hormone (AMH) levels predict the availability of good-quality supernumerary blastocysts for cryopreservation.
Two fertility centers.
First fresh IVF cycles (n = 247) grouped as follows: 40 women <35 year old with AMH <1 ng/mL and 77 women with AMH of 1–4 ng/mL; 62 women ≥35 year old with AMH <1 ng/mL, and 68 women with AMH 1–4 ng/mL. Intervention(s):
AMH level measured before IVF with ovarian stimulation protocols based on patient age and AMH level, including short gonadotropin-releasing hormone (GnRH) agonist, GnRH antagonist, or GnRH agonist microdose flare; supernumerary good-quality blastocysts cryopreserved on days 5 or 6 after retrieval.
Main Outcome Measures(s):
Supernumerary good-quality blastocysts for cryopreservation in relation to AMH levels.
Among women <35 years of age, there was a statistically significant difference in the number of supernumerary good-quality blastocysts for cryopreservation between the groups with AMH <1 ng/mL and AMH of 1–4 ng/mL (30.0% vs. 58.4%) when adjusted for age. Among women ≥35 years of age, there was a statistically significant difference in the number of supernumerary good-quality blastocyst cryopreservation between groups with AMH <1 ng/mL and AMH of 1–4 ng/mL (16.1% vs. 42.6%), when adjusted for age. Conclusion(s):
Low AMH levels are associated with a statistically significantly lower likelihood of blastocysts for cryopreservation as compared with higher AMH levels. This effect was seen among women both <35 and ≥35 years of age. Patient counseling should include realistic expectations for the probability of good-quality supernumerary blastocysts available for cryopreservation.